世界の多発性硬化症治療市場 – 業界動向と2030年までの予測

多発性硬化症治療市場の分析と規模

さまざまな感染症が世界の医療システムに与える負担の増大は主要な考慮事項であり、新興国が不釣り合いなほど多くの負担を負っています。インドの肝臓胆道科学研究所によると、世界の人口の約 3% が C 型肝炎ウイルスに感染しています。特に先進国と発展途上国の両方で HCV 感染の発生が世界的に増加していることが、世界の多発性硬化症治療市場の成長につながる主な要因です。

Data Bridge Market Research の分析によると、多発性硬化症治療薬市場は 2030 年までに 3,833 万ドル、2022 年には 2,575 万ドルに達し、2023 年から 2030 年の予測期間中に 5.10% の CAGR で成長する見込みです。市場価値、成長率、セグメンテーション、地理的範囲、主要プレーヤーなどの市場シナリオに関する洞察に加えて、Data Bridge Market Research がまとめた市場レポートには、詳細な専門家の分析、患者の疫学、パイプライン分析、価格分析、規制の枠組みも含まれています。

多発性硬化症治療薬市場の範囲とセグメンテーション

Market Definition

Multiple sclerosis (MS) is a chronic and inflammatory immune-mediated condition that can cause axonal transection, demyelination, and neurodegeneration of the spinal cord and brain nerve cells. Some of the frequently used therapies include the administration of injectable, oral and infused medicines, antidepressants, physical therapy and muscle relaxants.

Multiple Sclerosis Therapies Market Dynamics

Drivers

• Increasing Incidence of Multiple Sclerosis

There has been increasing occurrences of multiple sclerosis globally. According to the National Multiple Sclerosis Society’s study, around 1 million adults were suffering with multiple sclerosis in the U.S. in 2017. An estimated incidence of the disease was around 309 cases per 100,000 people in 2010, resulting in total of 727,344 multiple sclerosis cases among adults. According to the Government of Canada, more than 77,000 Canadians were surviving with multiple sclerosis of which 3/4th were women. The Multiple Sclerosis Society stated that about 110,000 people were suffering from the condition in the UK in 2018. It is also observed that MS is more than twice incident in females. The number of new patients diagnosed every year is also growing, which means that the number rise from 5,000 patients in 2017 to 6,700 in 2018. Thus, this incidence rate is boosting the demand for the treatment drugs.

Opportunities

• Increased R&D Activities by Organizations

Numerous drugs are in the research phase for the treatment of multiple sclerosis (MS) and many are undergoing clinical trials. U.S. FDA has approved several drugs for treating MS, namely fingolimod, interferons, natalizumab, glatiramer acetate, teriflunomide, and dimethyl fumarate. Several geneticists as well as other researchers are studying human genome for causes and other possible treatments for diseases such as muscular dystrophy, Alzheimer's, cancer and diabetes. For instance, they have found that some people with a specific gene are more likely to develop Alzheimer's disease. So researchers are now working on drugs that will modify or repair that particular gene. Likewise, many researchers have found that some people suffering from multiple sclerosis have a certain gene, making them more vulnerable to the disease. Hence, they are now consistently working on drugs that will either alter or repair that gene.

Restraints/Challenges

• High cost of Drugs

The cost of multiple sclerosis drugs remains a constant challenge to the market growth despite of the high prevalence of multiple sclerosis. The high pricing of drugs makes it inefficient to meet the needs pf the affected population. DMTs are the standard option for treatment but the extreme cost of these drugs leads to the improper adherence and disease management. As per the National Multiple Sclerois Society, the cost of MS drugs are increasing hugely. This factor is anticipated to limit the market growth.

This multiple sclerosis therapies market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the multiple sclerosis therapies market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments:

• In 2021, Janssen received U.S. FDA approval for Ponvory. It is a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator used to treat adults with relapsing forms of multiple sclerosis (MS), such as clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.
• In 2020, Novartis announced the US FDA approval for Kesimpta® in the form of an injection for subcutaneous use for treating the relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Global Multiple Sclerosis Therapies Market Scope

The multiple sclerosis therapies market is segmented on the basis of type, route of administration and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Immunosuppressants
• Humira
• Infliximab
• Immunomodulators
• Thalidomide
• Lenalidomide

Route of Administration

• Oral
• Injectable
• Intravenous

End-User

• Hospital and Clinics
• Diagnostic Laboratories
• Others

Multiple Sclerosis Therapies Regional Analysis/Insights

The multiple sclerosis therapies market is analyzed and market size insights and trends are provided by type, route of administration and end-user as referenced above.

The countries covered in the multiple sclerosis therapies market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the multiple sclerosis therapies market because of the strong demand for the multiple sclerosis drugs and increase in U.S. FDA approvals for medicines used in treating multiple sclerosis and improved healthcare system in this region.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 due to the improved pharmaceutical networks and initiatives to reduce costs in several regions .

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The multiple sclerosis therapies market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for multiple sclerosis therapies market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the multiple sclerosis therapies market. The data is available for historic period 2011-2021.

Competitive Landscape and Global Multiple Sclerosis Therapies Market Share Analysis

The multiple sclerosis therapies market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to multiple sclerosis therapies market.

Some of the major players operating in the multiple sclerosis therapies market are:

• AbbVie Inc. (U.S.)
• バウシュ・ヘルス・カンパニーズ（カナダ）
• バイオラ・セラピューティクス社（米国）
• ベーリンガーインゲルハイムインターナショナルGmbh（ドイツ）
• アムジェン社（米国）
• ファイザー社（米国）
• F. ホフマン・ラ・ロシュ社（スイス）
• マイランNV（米国）
• ノバルティスAG（スイス）
• バイエルAG（ドイツ）
• ブリストル マイヤーズ スクイブ カンパニー (米国)
• バイオジェン（米国）
• テバ製薬工業株式会社（イスラエル）
• 武田薬品工業株式会社（日本）
• ジャズ・ファーマシューティカルズ社（英国）
• アボット（米国）
• バイオ・ラッド・ラボラトリーズ社（米国）
• マイランNV（米国）

SKU-57194